INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] - On July 9, 2025, Mereo and Ultragenyx Pharmaceutical Inc. announced the progress of the Phase 3 Orbit study for UX143 (setrusumab) in patients with osteogenesis imperfecta, with a final analysis expected by the end of the year [2] - Following the announcement, Mereo's ADR price dropped by $1.25, or 42.52%, closing at $1.69 per share on July 10, 2025 [2] Group 2 - The Pomerantz Firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having pioneered the field of securities class actions over 80 years ago [3] - The firm has a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [3]